Webinar

Good Medicine: Solutions for Sensitive Injectable Formulations

Read description

How High Quality Film Coated elastomeric stoppers reduce patient and regulatory risk
 

Evaluating risk to the product dominates injectable drug development discussions. Risk not only means risk to the patient, but regulatory risk that impacts quality and possibly the bottom line. No company wants to find its drug product listed on the FDA Recalls list due to contamination such as the presence of particulates. Yet 11% of drug recalls in 2018 were due to foreign materials. As formulations become more sensitive, selection of elastomeric components that adapt to manufacturing processes as well as meet compatibility expectations are also a critical aspect of the product lifecycle. It took more 2 years to address a leachable interaction between an uncoated elastomer plunger and an erythropoietin formulation after it was withdrawn from the EU market and another four year commitment of immunogenicity monitoring to overcome this issue.

In this webinar, we will discuss how high quality film coated injectable components meet compliance expectations and maintain safety of supply for your drug product. This presentation will highlight how a proprietary film coating approach improves product robustness. From a manufacturing standpoint, continuous process improvements have been implemented that reduce contamination to achieve a 1.3 PCI specification. In addition, 100% inspection via visual systems helps prevent defects from entering the supply chain.

Elastomeric components are the major contributor to leachables in the drug product. A coated stopper solution mitigates the presence of leachables in the formulation preventing not only compatibility issues but also minimizing toxicity. A migration study was performed to evaluated potential leachables from both steam and gamma irradiated coated components. The results from this study, which demonstrated comparability in leachable profiles, will be presented during this webinar

By introduction of quality through technology, we will demonstrate the attributes of how film coated elastomer components improve managing component selection in a quality risk management environment. We hope that the content of this webinar is a dose of good medicine!

Presented by

Adam Shain Director, Global Business Development - Injectables
Adam Shain is the Global Business Development Director for Aptar Pharma's Injectables division and is responsible for driving the new business agenda with a particular focus on reinforcing the division's innovation proposition. Adam had previously worked for Promius Pharma, a subsidiary of Dr. Reddy's Laboratories, where he was instrumental in the development, commercialization, and launch of many of its branded products. Prior to his position at Promius, Adam was the associate director of business development for Aptar Pharma's prescription division.
Julie D. Suman President, Next Breath, an Aptar Pharma business
Julie D. Suman, R.Ph., Ph.D is the Founder of Next Breath, an Aptar Pharma business, and serves as its President. Dr. Suman holds a B.S. in Pharmacy from Duquesne University (1996) and a Ph.D. in Pharmaceutical Sciences from the University of Maryland, Baltimore (2002). Dr. Suman is co-editor for Respiratory Drug Delivery Proceedings, an international symposium, and an Affiliate Assistant Professor in the Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University. She is also a licensed Maryland pharmacist. Dr. Suman has published her research in peer-reviewed journals and has been presented during podium sessions at international meetings at the FDA Topics in Bioequivalence Seminar Series and has been an invited speaker at ANVISA in Brazil. Dr. Suman is also a member of the Parental Drug Association Visible Particulate Taskforce.
Please register to view the webinar :Already registered ?
Mandatory fields

*The information marked with (*) is essential to process your request. Failure to provide such information may prevent us from fulfilling your request. Your personal data will be used only for Aptar to process an information request and/or job application and will be made accessible to Aptar and to any third party for exclusively technical and logistical reasons, notably to our services located outside the European Union, being specified that, in the event that the recipient country does not ensure a level of data protection equivalent to that of the European Union, Aptar undertakes to take all relevant guarantees, either on the basis of an adequacy decision or, in the absence of such a decision, on the basis of appropriate safeguards, a copy of which may be requested from the contact email below. Your personal data will only be kept for a period that does not exceed the applicable statutory limitation periods. Any contact data will be made accessible to Aptar and to third parties that provide technical and logistical support to Aptar for the purpose of your contact request.

If any after communication upon receipt of a valid identity document, you have the right to access, modify, rectify, limit, delete and ask, if any, the portability of your personal data as well as a right of opposition, if necessary subject to legitimate and imperative reasons, to the processing of such data. You may also define guidelines for the use of your personal data in the event of death.

If you wish to exercise this option or if you have any questions regarding our General Terms and Conditions of Use, Privacy and Cookies Policy, please contact Aptar at: informationgovernance@aptar.com

You also have the right to lodge a complaint at the relevant data protection authority in your own jurisdiction.

October 24, 2018 3PM London / 10AM New York 60 min
Watch now
Presented by
Adam Shain Director, Global Business Development - Injectables
Julie D. Suman President, Next Breath, an Aptar Pharma business
Read more
Key Learning Objectives
  • How high quality film coated components address regulatory requirements
  • How to de-risk component selection process
  • Understand how process improvements can reduce contamination
  • Evaluate the impact of steam and gamma sterilization on elastomer components
Do you have questions about this webinar ?
Contact us